Nephrol Dial Transplant (2003) 18: 865-869
© 2003 European Renal Association-European Dialysis and Transplant Association
Editorial Comment
Pure red-cell aplasia due to anti-erythropoietin antibodies
1 Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow Klinikum, Berlin, Germany and 2 Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, Paris, France
Keywords: anti-erythropoietin antibodies; epoetin treatment; loss of efficacy; pure red-cell aplasia
| The first 150 words of the full text of this article appear below. |
Biopharmaceuticals generated by expression of DNA in cell lines have great potential for the treatment of diseases, in which the endogenous production of a specific protein is inadequately low and/or its administration has beneficial modulating effects on disease processes. Although these drugs are designed as copies of endogenous molecules, immunogenicity is a recognized risk. Factors that have been associated with an immunogenic potential include subtle differences in protein structure and in glycosylation (which is inherently variable), contaminants of the production process, the formulation, storage conditions, patient associated variables and the mode of application, with the i.v. route usually carrying the lowest risk [1].
Erythropoietin (Epo) produced by recombinant DNA technology (epoetin) is probably the most successful biopharmaceutical to date. It was introduced for the treatment of renal anaemia in the late 1980s as an i.v. drug. A few years later when first attempts were made to administer it
Prevalence of epoetin-induced PRCA
Definition and diagnosis of PRCA
Causes of epoetin-induced PRCA
Therapy
Preventive measures
Conclusions
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. L. Corwin and K.-U. Eckardt Erythropoietin in the critically ill: what is the evidence? Nephrol. Dial. Transplant., December 1, 2005; 20(12): 2605 - 2608. [Full Text] [PDF]
|
|
|
|
|
|
J. Andrade, P. A. Taylor, J. M. Love, and A. Levin Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2548 - 2551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Casadevall, K.-U. Eckardt, and J. Rossert Epoetin-Induced Autoimmune Pure Red Cell Aplasia J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S67 - S69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall, A. Roche, J. Rossert, N. Casadevall, P. Francois, and D. M. Kemeny Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2901 - 2905. [Full Text] [PDF]
|
|
|
|
|
|
D. Cournoyer, E. B. Toffelmire, G. A. Wells, D. L. Barber, B. J. Barrett, R. Delage, D. L. Forrest, R. F. Gagnon, E. A. Harvey, P. Laneuville, et al. Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia after Treatment with Recombinant Erythropoietin Products: Recommendations for Minimization of Risk J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2728 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schonholzer, G. Keusch, L. Nigg, D. Robert, and J.-P. Wauters High prevalence in Switzerland of pure red-cell aplasia due to anti-erythropoietin antibodies in chronic dialysis patients: report of five cases Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2121 - 2125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vartia, M. R. Asola, R. Tertti, P. Kunelius, and K. P. Metsarinne Two haemodialysis patients with epoetin alfa-induced pure red-cell aplasia recovered despite treatment with another epoetin preparation Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1313 - 1316. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gao, C. Lebherz, D. J. Weiner, R. Grant, R. Calcedo, B. McCullough, A. Bagg, Y. Zhang, and J. M. Wilson Erythropoietin gene therapy leads to autoimmune anemia in macaques Blood, May 1, 2004; 103(9): 3300 - 3302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, P. Aljama, P. Barany, B. Canaud, F. Carrera, K.-U. Eckardt, I. C. Macdougall, A. Macleod, W. H. Horl, A. Wiecek, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol. Dial. Transplant., February 1, 2004; 19(2): 288 - 293. [Full Text] [PDF]
|
|
|
|
|
|
J. Rossert, N. Casadevall, and K.-U. Eckardt Anti-Erythropoietin Antibodies and Pure Red Cell Aplasia J. Am. Soc. Nephrol., February 1, 2004; 15(2): 398 - 406. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Guest and L. Levitt Pure Red-Cell Aplasia Secondary to Antierythropoietin Antibodies N. Engl. J. Med., December 25, 2003; 349(26): 2572 - 2573. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giovannoni Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies Neurology, November 11, 2003; 61(90095): S13 - 17. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Radunovic, N. Parnell, M. Jackson, and P. Hill Another cause of anaemia QJM, October 1, 2003; 96(10): 775 - 776. [Full Text] [PDF]
|
|